Dianthus Therapeutics, Inc.
DNTH
Kedudukan dalam Saham
#4059
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in... Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Harga Saham
$73.08
Modal Pasaran
$4.09B
Perubahan (1 hari)
1.37%
Perubahan (1 tahun)
104.98%
Negara
US
Perdagangan Dianthus Therapeutics, Inc. (DNTH)
Kategori
Healthcare
Pendapatan untuk Dianthus Therapeutics, Inc. (DNTH)
Pendapatan pada Jun 2026 TTM: $-29.91M
Menurut laporan kewangan terkini Dianthus Therapeutics, Inc., pendapatan semasa syarikat ialah $-29.91M. Pada tahun 2023, syarikat memperoleh pendapatan sebanyak $-43.56M, penurunan berbanding pendapatan pada tahun 2022 yang berjumlah $-28.48M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Dianthus Therapeutics, Inc. dari 2016 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Ubah |
|---|---|---|
| 2026 (TTM) | $-29.91M | -64.80% |
| 2024 | $-84.97M | 95.08% |
| 2023 | $-43.56M | 52.95% |
| 2022 | $-28.48M | 117.22% |
| 2021 | $-13.11M | -82.51% |
| 2020 | $-74.94M | -2.39% |
| 2019 | $-76.77M | 33.48% |
| 2018 | $-57.52M | 62.06% |
| 2017 | $-35.49M | 276.32% |
| 2016 | $-9.43M | 0.00% |
Pendapatan untuk syarikat atau pesaing serupa
| Syarikat | Pendapatan | Perbezaan Pendapatan | Negara |
|---|---|---|---|
| $5.27B | -17,736.50% |
US
|
|
| $-3.09B | 10,221.31% |
US
|
|
| $-4.02B | 13,328.05% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -6,621.95% |
NL
|
